Figure 2. Lymphopenia induced by temolozomide in melanoma patients. Lymphocyte counts on freshly drawn blood samples (as assessed by flow cytometry) before the administration of temolozomide (TMD) and after the first, second and 3rd cycles of chemotherapy. **p < 0.01; ***p < 0.001 (paired Student's t-test).